Cidara Therapeutics, Inc. (CDTX) Earnings History
Net Loss13 years of earnings data (2012–2024) · Currently unprofitable on a TTM basis
Loading earnings history...
Cidara Therapeutics, Inc. (CDTX) Earnings Overview
As of June 20, 2026, Cidara Therapeutics, Inc. (CDTX) reported trailing twelve-month net income of -$185M, reflecting -409.5% year-over-year growth. The company earned $-11.88 per diluted share over the past four quarters, with a net profit margin of -13319.8%.
Looking at the long-term picture, CDTX's historical earnings data spans multiple years. The company achieved its highest annual net income of -$792,000 in fiscal 2012.
Cidara Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including ACAD ($376M net income, 36.5% margin), AGIO (-$423M net income, -764.0% margin), PRAX (-$327M net income), CDTX has room to improve margins relative to the peer group. Compare CDTX vs ACAD →
CDTX Earnings vs Peers
Earnings metrics vs comparable public companies
CDTX Historical Earnings Data (2012–2024)
13 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | -$170M | -640.6% | -$176M | $-26.75 | -13319.8% | -13811.9% |
| 2023 | -$23M | +31.7% | -$27M | $-5.25 | -98.5% | -116.2% |
| 2022 | -$34M | +20.9% | -$34M | $-9.61 | -52.1% | -52.0% |
| 2021 | -$42M | +41.1% | -$42M | $-16.19 | -85.7% | -85.2% |
| 2020 | -$72M | -75.5% | -$72M | $-36.03 | -597.6% | -595.4% |
| 2019 | -$41M | +30.4% | -$42M | $-26.78 | -196.5% | -199.5% |
| 2018 | -$59M | -5.9% | -$63M | $-45.62 | - | - |
| 2017 | -$56M | -15.7% | -$56M | $-63.69 | - | - |
| 2016 | -$48M | -49.6% | -$48M | $-66.49 | - | - |
| 2015 | -$32M | -170.7% | -$32M | $-46.76 | - | - |
| 2014 | -$12M | -785.0% | -$12M | $-290.15 | - | - |
| 2013 | -$1M | -69.7% | -$1M | $-83.04 | - | - |
| 2012 | $-792,000 | - | $-792,000 | $-0.25 | - | - |
Download Data
Export CDTX earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
14+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
CDTX — Frequently Asked Questions
Quick answers to the most common questions about buying CDTX stock.
What is CDTX earnings per share (EPS)?
CDTX trailing twelve-month (TTM) diluted EPS is $-11.88, reflecting -409.5% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2012 to 2024 is available in the table on this page.
What is Cidara Therapeutics, Inc.'s net income?
Cidara Therapeutics, Inc. (CDTX) trailing twelve-month net income is $-185M as of 2024. Earnings declined -409.5% year-over-year.
Is CDTX profitable?
CDTX is not currently profitable on a TTM basis, reporting a net loss of $-185M. Net margin is -13319.8%. Investors should monitor for a return to profitability.
What is CDTX's earnings growth rate?
CDTX compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2012 to 2024.
What are CDTX's profit margins?
Cidara Therapeutics, Inc. net profit margin is -13319.8%, operating margin is -13811.9%, and gross margin is +100.0%. Below-average margins reflect competitive or cost pressures. Return on Equity is -219.0%.
Is CDTX growing earnings?
CDTX earnings are declining — EPS fell -409.5% year-over-year. TTM net income dropped to $-185M. This contrasts with the 5-year CAGR of N/A.
What was CDTX's best earnings year?
Cidara Therapeutics, Inc.'s highest annual net income on record is $-792000.00, achieved in fiscal year 2012. Earnings history on this page spans 2012 to 2024 and includes all annual and quarterly figures.
What were CDTX's earnings last quarter?
CDTX's most recent reported quarter was Q3 2025. Net income was $-83M with diluted EPS of $-3.10. For a full breakdown of all quarters, see the quarterly earnings table on this page.